Get the Stockscreener App
27.73
16.78%
-5.59
Pre-market:
28.23
0.50
+1.80%
Doximity Inc stock is traded at $27.73, with a volume of 23.11M.
It is down -16.78% in the last 24 hours and down -39.31% over the past month.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
See More
Previous Close:
$33.32
Open:
$23.69
24h Volume:
23.11M
Relative Volume:
7.34
Market Cap:
$5.22B
Revenue:
$550.17M
Net Income/Loss:
$201.35M
P/E Ratio:
27.73
EPS:
1
Net Cash Flow:
$232.07M
1W Performance:
-25.99%
1M Performance:
-39.31%
6M Performance:
-52.30%
1Y Performance:
-52.40%
1-Day Range:
$23.66
$27.89
1-Week Range:
$23.66
$38.39
52-Week Range:
$23.66
$85.21
Doximity Inc Stock (DOCS) Company Profile
Name
Doximity Inc
Sector
Industry
Phone
(650) 549-4330
Address
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, TEM, BTSG, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
27.73 | 6.27B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
183.65 | 30.22B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
54.91 | 9.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
39.68 | 6.92B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
79.45 | 6.77B | 1.15B | 96.70M | -161.99M | 1.09 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Jan-08-26 | Upgrade | Truist | Hold → Buy |
| Dec-15-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-25 | Downgrade | Goldman | Neutral → Sell |
| Jul-09-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-02-25 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-07-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-07-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Nov-15-24 | Initiated | Goldman | Neutral |
| Nov-14-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-08-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Nov-08-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-09-24 | Upgrade | Needham | Hold → Buy |
| Jul-18-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Apr-25-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Jan-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-09-23 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-09-23 | Downgrade | Needham | Buy → Hold |
| Aug-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-01-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-31-22 | Initiated | Wells Fargo | Overweight |
| Oct-24-22 | Initiated | Evercore ISI | In-line |
| Oct-13-22 | Initiated | BTIG Research | Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-28-22 | Initiated | Berenberg | Buy |
| May-18-22 | Reiterated | BofA Securities | Neutral |
| May-18-22 | Reiterated | Goldman | Buy |
| May-18-22 | Reiterated | Guggenheim | Buy |
| May-18-22 | Reiterated | Jefferies | Buy |
| May-18-22 | Reiterated | Morgan Stanley | Equal-Weight |
| May-18-22 | Reiterated | Needham | Buy |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-04-22 | Initiated | BofA Securities | Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Dec-14-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Nov-17-21 | Initiated | Robert W. Baird | Outperform |
| Nov-10-21 | Reiterated | Canaccord Genuity | Buy |
| Nov-10-21 | Reiterated | Goldman | Neutral |
| Nov-10-21 | Reiterated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Reiterated | Needham | Buy |
| Nov-10-21 | Reiterated | Piper Sandler | Overweight |
| Aug-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-19-21 | Initiated | Canaccord Genuity | Buy |
| Jul-19-21 | Initiated | Goldman | Neutral |
| Jul-19-21 | Initiated | JP Morgan | Overweight |
| Jul-19-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-21 | Initiated | Piper Sandler | Overweight |
| Jul-19-21 | Initiated | Raymond James | Outperform |
| Jul-19-21 | Initiated | SVB Leerink | Outperform |
| Jul-19-21 | Initiated | William Blair | Outperform |
View All
Doximity Inc Stock (DOCS) Latest News
Canaccord Genuity upgrades Doximity stock to Buy on valuation - Investing.com
Assessing Doximity (DOCS) Valuation After A Sharp Pullback And Ongoing Profitability - Yahoo Finance
Doximity (DOCS) Earnings Call: AI, Buybacks and Growth - TipRanks
Doximity (NYSE:DOCS) Rating Increased to Moderate Buy at Needham & Company LLC - MarketBeat
Doximity Stock (-17%): Weak Guidance Sparks an Institutional Sell-Off - Trefis
JPMorgan upgrades Doximity stock rating to Neutral from Underweight By Investing.com - Investing.com Nigeria
Truist Securities lowers Doximity stock price target to $37 on growth concerns By Investing.com - Investing.com South Africa
Needham lowers Doximity stock price target to $55 on mixed earnings - Investing.com UK
Doximity (DOCS) Stock Plummets 17% on Weak Guidance and AI Cost Surges - FinancialContent
Doximity stock dives as Q4 outlook rattles investors despite $500 million buyback - TechStock²
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Doximity (NYSE:DOCS) Shares Gap DownWhat's Next? - MarketBeat
Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates - Yahoo Finance
Why Doximity stock plummeted today - MSN
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
Why Doximity Stock Plummeted Today - AOL.com
Doximity's Soft Fiscal Q4 Guidance Adds to Investor Concerns, Morgan Stanley Says - marketscreener.com
Doximity (NASDAQ:DOCS) Shares Gap Down After Analyst Downgrade - MarketBeat
Doximity stock price target lowered to $25 by BMO Capital on near-term headwinds - Investing.com
These Stocks Are Today’s Movers: Amazon, Strategy, Novo Nordisk, Molina, Stellantis, Impinj, Doximity, and More - Barron's
Truist Cuts Price Target on Doximity to $37 From $62, Keeps Buy Rating - marketscreener.com
Why Did DOCS Stock Plunge 35% In Pre-Market Today? - Asianet Newsable
Piper Sandler lowers Doximity stock price target to $40 on slow bookings - Investing.com
Doximity (DOCS) Q3 2026 Earnings Call Transcript - AOL.com
Needham lowers Doximity stock price target to $55 on mixed earnings By Investing.com - Investing.com South Africa
DOCS Q4 Deep Dive: AI Momentum Overshadowed by Pharma Budget Delays and Cautious Guidance - Finviz
Doximity (NASDAQ:DOCS) Upgraded to Neutral at JPMorgan Chase & Co. - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Doximity (NASDAQ:DOCS) Stock Price - MarketBeat
Morgan Stanley Lowers Doximity (NASDAQ:DOCS) Price Target to $49.00 - MarketBeat
BTIG Research Cuts Doximity (NASDAQ:DOCS) Price Target to $50.00 - MarketBeat
Doximity, Inc. (NYSE:DOCS) Q3 2026 Earnings Call Transcript - Insider Monkey
DOCS: Needham Lowers Price Target but Maintains Buy Rating | DOCS Stock News - GuruFocus
Doximity, Inc. (DOCS) Fell Following Disappointing Guidance - Insider Monkey
Doximity (DOCS) Fell Following Disappointing Guidance - Insider Monkey
JPMorgan Upgrades Doximity to Neutral From Underweight, Adjusts Price Target to $40 From $62 - marketscreener.com
Morgan Stanley Cuts Price Target on Doximity to $49 From $65, Keeps Overweight Rating - marketscreener.com
Doximity (DOCS) stock slips premarket after soft outlook, CFO medical leave, new $500 million buyback - TechStock²
S&P 500 Futures Climb in Premarket Trading; Doximity, Stellantis Lag - Barron's
Truist Securities lowers Doximity stock price target to $37 on growth concerns - Investing.com
Doximity Buyback Highlights Confidence In Telehealth Leadership And Long Term Story - Yahoo Finance
Doximity Q3 Earnings Call Highlights - MarketBeat
Assessing Doximity: Insights From 9 Financial Analysts - Benzinga
Doximity Stock Pre-Market (-38%): Weak Guidance Overshadows Earnings Beat - Trefis
Doximity slumps on weak fourth-quarter outlook - TradingView
JPMorgan upgrades Doximity stock rating to Neutral from Underweight - Investing.com
Doximity Inc (DOCS) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and AI Adoption ... By GuruFocus - Investing.com Canada
Decoding Doximity Inc (DOCS): A Strategic SWOT Insight - GuruFocus
Doximity outlines 4% Q4 revenue growth and projects double-digit exit rate for 2026 amid AI platform expansion - MSN
Stock Buyback Program Approved by Doximity (NASDAQ:DOCS) - MarketBeat
Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays - TipRanks
Doximity Inc Stock (DOCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):